Peptide · Vial
BPC 157
$8910mg
An experimental peptide best known for early research into tissue repair, tendon injury and wound response.
EternaGen / Research use onlyPeptide · Research use only
GHK-CU
From CA$54.99CAD
A naturally occurring copper-binding peptide explored in skin, collagen and wound-healing research.
Available to approved purchasers
Select strength
1
Documentation review pending Fulfilled in Canada Research use only
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
GHK-CU, clearly explained.
A naturally occurring copper-binding peptide explored in skin, collagen and wound-healing research.
Overview
GHK-Cu has been studied in human cells and in a small number of topical wound-care studies. Those findings are specific to the formulation and delivery method; they do not tell us what an injectable research material would do.
GHK-Cu is the copper complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine. Published work spans fibroblast models, skin-delivery experiments and a limited set of topical wound studies.- Format
- Vial
- Available strengths
- 50mg · 100mg
- Documentation
- Source review pending
Research at a glanceMechanistic and limited topical human evidence; injectable evidence limited
Reviewed 23 July 2026View research context Specifications
Product details
- Sequence / identity
- GHK-Cu
- Molecular weight
- 403.93 g/mol
- Storage and handling
- Protect from direct light. Refer to the batch record for compound-specific handling conditions.
Batch documentationSource review pending
Not yet publishedSupplier-origin documentation will be published only after EternaGen verifies the source and record details.
Important research-use boundary
Health Canada lists the named compound or components among unauthorized injectable drugs identified in the Canadian market. A research-use label does not make an unauthorized product suitable or legal for personal use.
Explore the research
What has been studied?
Keep the context attached
Check what was studied, what researchers observed, and the limitation attached to each finding.
Question 01
Extracellular-matrix biology
Human fibroblast cultures have shown concentration-dependent changes in collagen and matrix-related markers.
Evidence so far: In-vitro human-cell evidenceQuestion 02
Topical wound research
An older controlled study evaluated a GHK-Cu gel as part of standardized care for diabetic neuropathic ulcers.
Evidence so far: Narrow topical human evidenceQuestion 03
Route matters
Topical or ex-vivo skin findings do not establish the safety or effects of an injectable product.
Evidence so far: Critical interpretation boundaryProposed mechanism
How researchers are investigating the mechanism.
GHK binds copper(II), a metal involved in multiple enzymes. Laboratory studies have reported changes in collagen synthesis, glycosaminoglycans and extracellular-matrix remodelling, but the effect depends on concentration, formulation and experimental system.
Evidence gaps
What remains unknown?
- The amount of evidence for systemic or injectable administration is very limited.
- Formulation, copper stoichiometry, stability and route can materially change what is being studied.
- Evidence for a topical clinical formulation cannot be transferred to a research vial.
Primary sources
Check the original sources.
- Primary mechanistic studyMaquart et al. GHK-Cu and collagen synthesis in fibroblast cultures. FEBS Lett. 1988. PMID 3169264.
- Primary topical clinical studyMulder et al. GHK-Cu gel in diabetic neuropathic ulcers. Wound Repair Regen. 1994. PMID 17147644.
- Regulatory safety reviewU.S. FDA. GHK-Cu injectable-route safety considerations.
Related products
Continue comparing.
Peptide · Pen
MOTS-c
From CA$6410mg20mg
A peptide made inside mitochondria and studied for its connection to energy, exercise and metabolic stress.
Peptide · Vial
Tesamorelin
From CA$10910mg20mg
A synthetic peptide that mimics a natural signal involved in the release of growth hormone.